
Invitae Corporation NVTA
Quarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Shares 2011-2026 | NVTA
Annual Shares Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 236 M | 211 M | 135 M | 90.9 M | 66.7 M | 46.5 M | 33.2 M | 28.2 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 236 M | 28.2 M | 106 M |
Quarterly Shares Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 276 M | 264 M | 250 M | - | 238 M | 232 M | 228 M | 228 M | 218 M | 204 M | 194 M | 186 M | 132 M | 129 M | 99.6 M | 98.8 M | 95.6 M | 90.9 M | 79.4 M | 75.5 M | 70.2 M | 67.8 M | 54.4 M | 53.6 M | 48.2 M | 43.2 M | 42.3 M | 41.1 M | 32.3 M | 32.2 M | 32 M | 31.9 M | 31.9 M | 31.8 M | 17.1 M | 945 K | 886 K | 823 K | 749 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 276 M | 749 K | 104 M |
Shares of other stocks in the Diagnostics research industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
20.9 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
82.2 M | - | -61.36 % | $ 2.46 M | ||
|
Agilent Technologies
A
|
304 M | $ 115.55 | 3.81 % | $ 35.1 B | ||
|
CareDx, Inc
CDNA
|
53.3 M | $ 20.81 | 0.05 % | $ 1.11 B | ||
|
Co-Diagnostics
CODX
|
1.33 M | $ 1.55 | 1.31 % | $ 2.06 M | ||
|
Castle Biosciences
CSTL
|
27.8 M | $ 24.49 | 1.03 % | $ 680 M | ||
|
Akumin
AKU
|
89.5 M | - | -17.87 % | $ 25.9 M | ||
|
Biocept
BIOC
|
17 M | - | -13.05 % | $ 7.29 M | ||
|
Fulgent Genetics
FLGT
|
30.2 M | $ 15.19 | 2.64 % | $ 459 M | ||
|
Aspira Women's Health
AWH
|
34.1 M | - | -6.19 % | $ 10.5 M | ||
|
Chembio Diagnostics
CEMI
|
32.3 M | - | 0.22 % | $ 16.8 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
26.6 M | - | - | $ 562 M | ||
|
Check-Cap Ltd.
CHEK
|
5.85 M | - | - | $ 9.42 M | ||
|
Heska Corporation
HSKA
|
10.3 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
889 K | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
82.5 M | $ 118.33 | 1.86 % | $ 9.76 B | ||
|
Illumina
ILMN
|
159 M | $ 126.74 | 5.29 % | $ 20.2 B | ||
|
DermTech
DMTK
|
32.6 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
122 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
74.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
461 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
49.6 M | $ 166.97 | 1.91 % | $ 8.28 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
63.8 M | - | - | $ 10.7 B | ||
|
Lantheus Holdings
LNTH
|
67.5 M | $ 84.62 | 4.25 % | $ 5.71 B | ||
|
Enzo Biochem
ENZ
|
50.9 K | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
189 M | - | - | $ 19.8 B | ||
|
Medpace Holdings
MEDP
|
28.8 M | $ 418.66 | 1.23 % | $ 12.1 B | ||
|
Guardant Health
GH
|
125 M | $ 87.08 | 4.4 % | $ 10.9 B | ||
|
Motus GI Holdings
MOTS
|
1.55 M | - | -34.28 % | $ 263 K | ||
|
Koninklijke Philips N.V.
PHG
|
904 M | $ 26.34 | 2.95 % | $ 20 B | ||
|
Myriad Genetics
MYGN
|
92.6 M | $ 4.75 | 1.5 % | $ 440 M | ||
|
Interpace Biosciences
IDXG
|
4.42 M | $ 1.98 | -0.5 % | $ 8.76 M | ||
|
NeoGenomics
NEO
|
128 M | $ 9.26 | 3.35 % | $ 1.19 B | ||
|
QIAGEN N.V.
QGEN
|
217 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
2.3 M | $ 2.18 | 0.93 % | $ 5.01 M | ||
|
Laboratory Corporation of America Holdings
LH
|
83.2 M | $ 256.8 | -0.13 % | $ 21.4 B | ||
|
National Research Corporation
NRC
|
22.4 M | $ 16.46 | -0.48 % | $ 368 M | ||
|
Celcuity
CELC
|
46.8 M | $ 121.35 | 1.97 % | $ 5.67 B | ||
|
Natera
NTRA
|
98.4 M | $ 206.16 | 5.86 % | $ 20.3 B | ||
|
Neogen Corporation
NEOG
|
217 M | $ 9.4 | 4.33 % | $ 2.04 B | ||
|
Quest Diagnostics Incorporated
DGX
|
111 M | $ 194.2 | 2.58 % | $ 21.6 B | ||
|
OpGen
OPGN
|
4.66 M | - | -16.95 % | $ 1.54 M | ||
|
Organovo Holdings
ONVO
|
1.46 M | - | -2.3 % | $ 19.4 M | ||
|
PerkinElmer
PKI
|
117 M | - | -0.91 % | $ 14.7 B | ||
|
Exagen
XGN
|
21.6 M | $ 2.9 | 5.07 % | $ 62.5 M | ||
|
Precipio
PRPO
|
1.61 M | $ 30.9 | 3.21 % | $ 49.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
82.1 M | $ 17.0 | 4.68 % | $ 179 M | ||
|
Personalis
PSNL
|
59.3 M | $ 5.52 | 9.52 % | $ 327 M |